Impact of renin–angiotensin system inhibitors discontinuation in advanced chronic kidney disease: a target trial emulation
ABSTRACT Background Renin–angiotensin system (RAS) inhibitors are a cornerstone of cardiovascular and kidney risk modification in chronic kidney disease (CKD). Yet, they are often discontinued in advanced CKD to limit adverse effects or to delay kidney replacement therapy (KRT). Methods From the CKD-Renal Epidemiology...